EMA panel backs daraxonrasib for pancreatic cancer after sub-150-day review
The EMA's human medicines committee recommended EU approval of Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer, citing median survival of 12.4 months versus 6.7 on chemotherapy.